[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371034-105":59,"doc-detail-371034-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancing-the-antitumor-efficacy-using-a-combination-of-fgfr4-inhibitor-h3b-6527-and-oxaliplatin-in-gastric-cancer-original-research","Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer - Original Research","","Oxaliplatin is a standard platinum-based therapy for gastrointestinal cancers, but gastric tumors often develop resistance that worsens outcomes. This study evaluates whether combining the FGFR4 inhibitor H3B-6527 with oxaliplatin improves antitumor activity in gastric cancer models. In vitro, the combination reduces viability and clonogenic survival versus either agent alone, with oxaliplatin resistance linked to increased FGFR4 expression. Mechanistically, enhanced DNA damage and apoptosis occur alongside suppressed pro-survival signaling. In patient-derived xenografts and tumoroids, the combined treatment lowers tumor growth and improves survival, supporting FGFR4-targeted clinical trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-the-antitumor-efficacy-using-a-combination-of-fgfr4-inhibitor-h3b-6527-and-oxaliplatin-in-gastric-cancer-original-research/371034/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-the-antitumor-efficacy-using-a-combination-of-fgfr4-inhibitor-h3b-6527-and-oxaliplatin-in-gastric-cancer-original-research/371034.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is resistance to oxaliplatin a problem in gastric cancer?","Question",{"text":112,"@type":113},"Platinum-based therapy resistance leads to poor clinical outcomes and limits effectiveness in advanced disease. The study highlights an urgent need for strategies that can overcome this resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does H3B-6527 add to oxaliplatin treatment?",{"text":117,"@type":113},"Combining H3B-6527 with oxaliplatin significantly reduces gastric cancer viability and clonogenic survival compared with either treatment alone, indicating improved antitumor efficacy.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanisms support the enhanced treatment effect?",{"text":121,"@type":113},"The combination amplifies DNA damage and increases apoptosis while suppressing pro-survival pathways, supported by assays measuring markers such as γH2AX, cleaved PARP, and Caspase-3/7.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371034,1790726568,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Neoplasia 71 (2026) 101257  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer |  |  | |\n| --- | --- | --- | --- |\n| Nadeem Bhata,1 , Mohammed Souttoa,b,1 , Zheng Chena,c, Marwah Al-Mathkoura, Silvia Giordano d, Mohammed Chwihnea, Melanie Genoulaa , Farah Ballouta, Shoumin Zhu a , Oliver G McDonald e, Wael El-Rifai *,a,b,c \u003Cbr>a Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA b Department of Veterans Affairs, Miami Healthcare System, Miami, FL, USA\u003Cbr>c Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA d Department of Oncology, University of Torino and Candiolo Cancer Institute, Candiolo, Italy\u003Cbr>e Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: Gastric cancer FGFR4\u003Cbr>Oxaliplatin H3B-6527 |  | Oxaliplatin, a platinum-based anticancer drug, is commonly used to treat gastrointestinal cancers, including gastric cancer. However, resistance to platinum-based therapies often leads to poor clinical outcomes for gastric cancer patients. Overexpression and activation of FGFR4 signaling have been identified as drivers of tumorigenesis in several types of cancer, including gastric cancer. In this study, we investigated the therapeutic efficacy of combining the FGFR4 inhibitor H3B-6527 with oxaliplatin using in vitro and in vivo gastric cancer models. Using gastric cancer cell lines, cell viability and clonogenic cell survival assays revealed that the combination treatment significantly reduced cancer cell viability and colony formation, compared to either agent alone (p \u003C 0.01). Interestingly, treatment with oxaliplatin alone increased FGFR4 expression in the resistant cancer cell population. Western blot analysis confirmed the heightened DNA damage (γH2AX, cleaved PARP) alongside suppressed pro-survival signals (phospho-STAT3 and BCL2 family). Apoptosis was markedly enhanced, as demonstrated by Caspase-3/7 and TUNEL assays (p \u003C 0.01). In human gastric cancer-derived tumoroids, the combination therapy significantly reduced both the size and number of tumoroids. In patient-derived xenograft (PDX) models, the combined treatment approach outperformed single-agent treatments in reducing tumor growth and improving survival. Immunofluorescence and immunohistochemistry analyses of PDX tumors showed an increase in DNA damage (γH2AX) and apoptosis (cleaved caspase-3) along with a reduction in cell proliferation (KI67).\u003Cbr>These findings indicate that H3B-6527 enhances gastric cancer sensitivity to oxaliplatin by amplifying DNA damage and disrupting cell survival pathways. This study provides a rationale for clinical trials targeting FGFR4 in gastric cancer. |  |\n\nIntroduction  \nGastric cancer is a prevalent malignancy worldwide, ranking as the fifth most common cancer and the fourth leading cause of cancer-related mortality globally [1,2]. The American Cancer Society projects around approximately 30,300 new cases of gastric cancer in the United States by 2025, with 17,720 cases in men and 12,580 in women, resulting in an estimated 10,780 deaths [3]. Despite advancements in surgical  \ntechniques and systemic therapies, the prognosis for patients with advanced gastric cancer remains poor. The overall five-year relative survival rate for gastric cancer is approximately 36 %, dropping significantly to single digits in patients with advanced disease (stage III or IV)  \n[4]. Current treatment options primarily involve combinations of chemotherapy, targeted therapy, and immunotherapy. However, the emergence of treatment resistance and disease progression underscore the urgent need for i","cbCaifThyeImWfAq","https://ap.wps.com/l/cbCaifThyeImWfAq","pdf",10562516,12,"English","# Introduction\n## FGFR4 in cancer and therapeutic resistance\n## Oxaliplatin and gastric cancer treatment\n## Rationale for combination therapy","[{\"question\":\"Why is resistance to oxaliplatin a problem in gastric cancer?\",\"answer\":\"Platinum-based therapy resistance leads to poor clinical outcomes and limits effectiveness in advanced disease. The study highlights an urgent need for strategies that can overcome this resistance.\"},{\"question\":\"What does H3B-6527 add to oxaliplatin treatment?\",\"answer\":\"Combining H3B-6527 with oxaliplatin significantly reduces gastric cancer viability and clonogenic survival compared with either treatment alone, indicating improved antitumor efficacy.\"},{\"question\":\"What mechanisms support the enhanced treatment effect?\",\"answer\":\"The combination amplifies DNA damage and increases apoptosis while suppressing pro-survival pathways, supported by assays measuring markers such as γH2AX, cleaved PARP, and Caspase-3/7.\"}]","Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer - Original Research | PDF",1790191085,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99e16fb34a17daa46cc2085784620f3c.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b369605b6e5ddacf23eb711818e547e7.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96c9f9acaf28c2edec58e6e771c8b593.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2e594c79e3f44d1b2822c4638fd40ac.webp",980,1306]